Skip to main content
Clinical Trials/NCT01829945
NCT01829945
Completed
Not Applicable

Study of the Relationships Between Apolipoprotein B-48 Kinetics and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With the Metabolic Syndrome.

Laval University1 site in 1 country30 target enrollmentOctober 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Syndrome X
Sponsor
Laval University
Enrollment
30
Locations
1
Primary Endpoint
Change in TRL apolipoproteinB-48 production rate.
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

Several lines of evidence indicate that a significant proportion of cardiovascular disease (CVD) events are attributable to the presence of a cluster of metabolic abnormalities and perturbations, defined as the metabolic syndrome. It has been estimated that approximately 25% of the North American adult population is living with the metabolic syndrome. Recent studies show that overaccumulation of atherogenic triglyceride-rich lipoproteins (TRL) seen in insulin-resistant patients is partly due to increased production rate of intestinally derived apolipoproteinB-48-containing lipoproteins. This is of interest because substantial evidence exists indicating that elevated levels of intestinal lipoproteins are associated with increased CVD risk. However, as indicated in the body of this grant proposal, the underlying mechanisms that lead to intestinal overproduction of lipoproteins in insulin-resistant states are poorly understood.

The general objective of the proposed research is to investigate the mechanisms by which the metabolic syndrome affects apolipoproteinB-48 secretion in human. The primary hypothesis is that insulin resistance will be associated with higher levels of intestinal lipoproteins because of an increased secretion of these particles.

Registry
clinicaltrials.gov
Start Date
October 2009
End Date
February 2011
Last Updated
13 years ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Patrick Couture

MD, FRCP, PhD

Laval University

Eligibility Criteria

Inclusion Criteria

  • Subjects with metabolic syndrome:
  • Men aged between 18-60 years
  • Waist circumference \>102
  • HDL-cholesterol \< 1.1 mmol/L
  • Triglycerides \> 1.7 mmol/L
  • Fasting blood glucose \>6.1 mmol/L
  • Normal blood pressure (\<130/85)
  • Men aged between 18-60 years
  • Waist circumference \>102
  • HDL-cholesterol \> 1.1 mmol/L

Exclusion Criteria

  • Men \< 18 or \> 60 years
  • Smokers (\> 1 cigarette/day)
  • Body weight variation \> 10% during the last 6 months prior to the study baseline
  • Subjects with a previous history of cardiovascular disease
  • Subjects with Type 2 diabetes
  • Subjects with a monogenic dyslipidemia
  • Subjects on hypertension medications or medications known to affect lipoprotein metabolism or the integrity of gastrointestinal mucosa
  • Subjects with endocrine or gastrointestinal disorders
  • History of alcohol or drug abuse within the past 2 years
  • Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study

Outcomes

Primary Outcomes

Change in TRL apolipoproteinB-48 production rate.

Time Frame: Week 1

Secondary Outcomes

  • Changes in duodenal expression of genes that regulate intestinal lipid absorption.(Week 1)
  • Change in synthesis of apolipoproteinB-48 containing lipoproteins (Microsomal triglyceride transfer protein (MTP), apolipoproteinB-48).(Week 1)
  • Change in duodenal expression of genes that regulate intestinal lipid synthesis.(Week 1)

Study Sites (1)

Loading locations...

Similar Trials